Antibe Therapeutics Inc (ATE) 뉴스

Well the tablet re-formulation ended up being very costly from both a time and money perspective, so this pivot/re-formulation really better pay off with stellar p2 results. Hopefully we get the readout data prior to the end of Q2 2024. I still see this as a strong risk/reward setup, it’s just been the opportunity cost of having tied up the funds. Interest in the share price should pick up heading into Q1.

This board is a ghost town.

My take on thecurrent situation with Antibe:

With a current $25M CAD m/c I think the risk/reward setup here is about 20% risk for 300%+ reward leading up to the phase 2 acute otena readout by late 2023. Worthy of a on of due diligence since there’s been a lot of costlyhiccups with this company but the shares are currently trading as though none of the underlying fundamentals matter at all.

The company has more than enough cash to fund the ph2 trial. They have pivoted from chronic to the acute pain market which, while smaller annual peak sales, offers a far more de-risked pathway to positive ph2 readout results and inevitable commercialization/buyout post ph3. The IP reformulation also demonstrably helps de-risk the results with a more rapid onset and significantly reduced dosing regime. This could enable them, once funds allow, to go back to chronic otena for a ph3. But the sweet spot is here and now for those with funds and about one year of patience.

What I’ve learned with biotechs is know your company very well but as important, know the cycle of when time and money are on your side or when they’re against you. All in my opinion.

https://m.canadianinsider.com/node/7?ticker=ATE&fbclid=IwAR3q4E-W8ZRcSlyhCwwamdTOLXDHInLgVBGQMvuMDbrVj6Vy21eyzl-sN3M

https://www.biospace.com/article/releases/antibe-therapeutics-provides-clinical-update-for-otenaproxesul/

Received proxy material

https://www.lelezard.com/en/news-19876628.html

**Attention Accredited Investor and Shareholders**
Please feel free to tune in to hear directly from management in an exclusive Zoom presentation for accredited investors and shareholders. Company executives will be giving an overview of the story while discussing upcoming catalysts and answering live questions. Register using the link below:

https://www.eventbrite.com/e/antibe-therapeutics-inc-webinar-6222021-registration-159355880729?ref=enivtefor001&invite=MjA1MDk0NjcvZ3RvZGRtYXJrZXlAZ21haWwuY29tLzA%3D%0A&utm_source=eb_email&utm_medium=email&utm_campaign=inviteformalv2&utm_term=eventpage

FDA clearance a bit dated but opens up US for stage 3 trials. Pretty sweet imo.

Antibe Therapeutics Receives FDA Clearance of IND Application for Otenaproxesul for Osteoarthritis Pain http://ca.finance.yahoo.com/news/antibe-therapeutics-receives-fda-clearance-110000132.html?soc_src=community&soc_trk=ma

Flying low under the USA radar.

https://antibethera.com/

I’m pretty sure not many have looked into the potential this one has.
Long and IMO of coarse.

Yeah, baby!

$5 US. That’s pretty.

After a long time - company found a partner and some funding.
Hopefully now they can move forward and give good results.
The product is good and has big potential in US

Excellent news, kudos to Dan and his team on this. More partnerships to come. Load up at these levels, still way undervalued!

https://finance.yahoo.com/news/antibe-therapeutics-announces-strategic-licensing-120000925.html

Ring the bell at tsx. Amazing what some exposure can do

ATBPF one for 10 reverse split. **PPS closed at .30

https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes

Not great seemingly

See how the Canadian up listing will treat the stock. Positive so far with announcement

386,782,798 added another million plus to the o/s

Interesting biotech that has almost no volume, compared to similar ones, maybe the volume is north of the border?

The Drug and potential is very interesting. On my radar now.

Will major news and whole lot volume to break and run big time.

And time line on the Phase III trial?

more added, outstanding now 385,516,301
they added +100 million shares since last year.

continues to be shit on

added 19 million shares since 3/30, is this another dilution pos

continues to be shit on

Halt!

Heard the cc and Q&A

They were all very positive - all plan for next steps.

The phase 2/3 is good but with 12 week trial with 300+ patients and split into 2 phases - I think it is a long road and funding may be an issue.

Yeah, not sure if people were just expecting a blow up instantly, but with the current MC to the potential I think we should see some real growth and pops at in partnership and other milestone. This is a multi dollar stock.

wow, but continued doo-doo-ing in the stock - big volume

Everything positive from the CC. lots of details, i believe they will put the transcript up on the website. Timelines haven't changed. everything moving forward as planned on better than expected results.

great - pls let us know what you think

I’m on it

can’t make it - can anyone else?

Conference call June 4

Especially given the volume here two days of very heavy downward volume

Agree - I cannot see any update from company or someone on why such a bad reaction.
I thought the results were good

i am surprised by the degree of the sell off here

I sold 30k at .45 and got out, should have sold friday, better not complain as douled money and dont like the action, good news and fall ? im moving on!

happens often, investors buy the rumor/speculation, then sell the news.
good luck

The market is failing to price these results into the share price. Wasn’t expecting shares to go down on positive news. What was the market expecting here, FDA approval. Any guesses as to stock performance? This company is very undervalued for its stage of development and product pipeline.

Very good news Amatuer17.

Results out - they look very good as expected.

All 3 doses showed very good results and top 2 doses showed statistical significance . New registrational pivotal P2/3 trial being planned.


https://finance.yahoo.com/news/antibe-therapeutics-announces-positive-top-103000987.html

Woot! Ty!

https://www.bnnbloomberg.ca/video/robert-mcwhirter-discusses-antibe-therapeutics~1968070

So what I miss lol?

https://www.facebook.com/watch/?v=365342554408162

I expected a delay, just not that much. I have a feeling it will be 2-3 weeks and they wanted to be safe give themselves a buffer zone.

Great hire in Dr Stauffer as Chief Medical Officer. Shows management’s confidence in P2b.

Another 6 weeks, apparently.....

6 more weeks - well at least they have all the data and no impact on trial parameters.


https://finance.yahoo.com/news/antibe-therapeutics-updates-timing-top-103000962.html